Opinion/decision on a Paediatric investigation plan (PIP): Live, attenuated, dengue virus, serotype 1 (DENV1),Live, attenuated, chimeric dengue virus, serotype 2 (DENV2),Live, attenuated, dengue virus, serotype 3 (DENV3),Live, attenuated, dengue virus, serotype 4 (DENV4), decision type: , therapeutic area: , PIP number: P/0521/2022

Opinion/decision on a Paediatric investigation plan (PIP): Manganese chloride tetrahydrate, decision type: , therapeutic area: , PIP number: P/0498/2022

Opinion/decision on a Paediatric investigation plan (PIP): Depemokimab, decision type: , therapeutic area: , PIP number: P/0543/2022

Opinion/decision on a Paediatric investigation plan (PIP): Enzastaurin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0544/2022

Opinion/decision on a Paediatric investigation plan (PIP): dolutegravir,HIV-1 Maturation Inhibitor (GSK3640254), decision type: , therapeutic area: , PIP number: P/0523/2022

Opinion/decision on a Paediatric investigation plan (PIP): Constella,linaclotide, decision type: , therapeutic area: , PIP number: P/0529/2022

Opinion of the CVMP on the establishment of maximum residue limits: Praziquantel

Human medicines European public assessment report (EPAR): Sildenafil Actavis, sildenafil, Erectile Dysfunction, Date of authorisation: 10/12/2009, Revision: 17, Status: Authorised

Guide to information on human medicines evaluated by European Medicines Agency: what the Agency publishes and when

Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure